<DOC>
	<DOCNO>NCT00820755</DOCNO>
	<brief_summary>This open-label , randomize , multinational , non-comparative , phase IIIb trial 2 parallel group screen 1400 subject stage IIIB non-small cell lung cancer ( NSCLC ) pleural effusion stage IV NSCLC . It expect approximately 1200 ( 85 percent ) subject include , 1000 Caucasian ; 120 Asian , remainder ( 80 ) ethnic origin ( neither Caucasian Asian ) . Approximately 480 ( 40 percent ) subject expect free progression end combination treatment cetuximab platinum-based chemotherapy . These subject eligible randomization intravenous cetuximab maintenance therapy either 500 milligram per square meter ( mg/m^2 ) every 2 week 250 mg/m^2 weekly ( q1w ) ; 240 subject expect per group . The trial perform community practice setting , approximately 230 center participate trial worldwide ( planned country Argentina , Australia , Austria , Belgium , Brazil , Chile , China , Colombia , Czech Republic , France , Germany , Greece , Hong Kong , Hungary , India , Ireland , Israel , Italy , Mexico , Netherlands , Poland , Portugal , Russia , Singapore , Slovakia , South Africa , South Korea , Spain , Switzerland , Taiwan , Turkey , United Kingdom Venezuela ) . With noncompetitive enrollment , approximately 4 8 subject expect enrolled center . Enrollment individual center generally limit maximum 8 subject . If subject receive trial treatment reason discontinue trial treatment first visit , additional subject may enrol 8 subject treat . The primary endpoint trial overall survival time inclusion trial death . Additional secondary efficacy endpoint time treatment failure , tumor response , disease control rate . Other endpoint include safety toxicity , compliance maintenance therapy , subject satisfaction translational research ( TR ) ( subject tumor sample available ) .</brief_summary>
	<brief_title>Trial With Cetuximab Maintenance Therapy After Platinum Based Chemotherapy First Line Treatment Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subject give write informed consent trialrelated activity carry Male female , great equal ( &gt; = ) 18 year age time informed consent , inpatient outpatient Diagnosis histologically cytologically confirm NSCLC , stage IIIB NSCLC pleural effusion stage IV Presence least 1 unidimensionally measurable index lesion , whereby index lesion must lie previously irradiate area Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 inclusion trial White blood count &gt; = 3 * 10^9 per liter ( /L ) neutrophils &gt; = 1.5 * 10^9 /L , platelet count &gt; =100 * 10^9 /L , hemoglobin &gt; = 5.6 millimole per liter ( mmol/L ) ( 9 gram per deciliter [ g/dL ] ) Total bilirubin less equal ( = &lt; ) 1.5 * upper limit normal ( ULN ) range Aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) = &lt; 5 * ULN Glomerular filtration rate ( GFR ) &gt; =60 milliliter per minute ( mL/min ) . The creatinine clearance ( CrCl ) estimate base CockroftGault formula use surrogate GFR Effective contraception , barrier method ( condom , diaphragm ) , oral , injectable implant birth control , male female subject whole trial period least 6 month end trial treatment , risk conception exists Recovered relevant toxicity prior inclusion trial Previous exposure Epidermal Growth Factor Receptor ( EGFR ) target therapy Previous chemotherapy NSCLC ; neoadjuvant adjuvant ( radio ) chemotherapy allow finish 6 month prior start trial treatment Major surgery within 30 day prior inclusion trial Prior chest irradiation within 90 day prior inclusion trial ( palliative radiation bone lesion allow ) Participation another clinical trial treatment investigational agent ( ) within 30 day prior inclusion trial Concurrent chronic systemic immune therapy , chemotherapy disease cancer , hormone therapy treatment cancer indicate trial protocol Documented symptomatic brain metastasis Preexisting ascites Grade &gt; = 2 and/or pericardial effusion Grade &gt; = 2 Superior vena cava syndrome contraindicate hydration Previous malignancy last 5 year except basal cell carcinoma skin preinvasive carcinoma cervix Active infection ( infection require intravenous antibiotic ) , include active tuberculosis , know declared human immunodeficiency virus ( HIV ) Myocardial infarction within 6 month prior inclusion trial , uncontrolled congestive heart failure ; current Grade 3 4 cardiovascular disorder despite treatment Known hypersensitivity reaction component trial treatment Symptomatic peripheral neuropathy National Cancer InstituteCommon Toxicity Criteria ( NCICTC ) Grade &gt; = 2 and/or ototoxicity Grade &gt; = 2 , except due trauma mechanical impairment due tumor mass History significant neurologic psychiatric disorder include dementia , seizure , bipolar disorder Medical psychological condition would permit subject complete trial sign inform consent Legal incapacity limit legal capacity Known drug abuse Pregnancy ( absence confirm serum betahuman chorionic gonadotropin [ betaHCG test ] ) lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>